4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) CEO David Kirn sold 12,930 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $23.10, for a total transaction of $298,683.00. Following the completion of the transaction, the chief executive officer now owns 1,059,153 shares of the company's stock, valued at approximately $24,466,434.30. The sale was disclosed in a filing with the SEC, which is accessible through this link.
4D Molecular Therapeutics Stock Performance
FDMT opened at $21.01 on Thursday. 4D Molecular Therapeutics, Inc. has a 1-year low of $9.44 and a 1-year high of $36.25. The firm has a 50-day moving average price of $24.58 and a two-hundred day moving average price of $24.64.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its earnings results on Thursday, May 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.07. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $1.44 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 26.75%. As a group, equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -2.98 earnings per share for the current year.
Institutional Inflows and Outflows
We recommended Nvidia in 2016, now we’re recommending this…
From Porter & Company | Ad
The AI boom is just getting started.
And the real wealth has still to be made…
You must read this new presentation from Porter Stansberry.
Several hedge funds have recently modified their holdings of FDMT. Bfsg LLC bought a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at about $30,000. China Universal Asset Management Co. Ltd. boosted its stake in 4D Molecular Therapeutics by 359.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company's stock worth $100,000 after acquiring an additional 3,873 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in 4D Molecular Therapeutics by 702.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company's stock worth $110,000 after acquiring an additional 3,026 shares during the last quarter. Daiwa Securities Group Inc. boosted its stake in 4D Molecular Therapeutics by 23.3% during the 4th quarter. Daiwa Securities Group Inc. now owns 5,872 shares of the company's stock worth $119,000 after acquiring an additional 1,110 shares during the last quarter. Finally, Entropy Technologies LP bought a new position in 4D Molecular Therapeutics during the 1st quarter worth approximately $239,000. Institutional investors own 99.27% of the company's stock.
Analyst Upgrades and Downgrades
FDMT has been the subject of a number of recent research reports. Royal Bank of Canada restated an "outperform" rating and issued a $40.00 price objective on shares of 4D Molecular Therapeutics in a research note on Wednesday. BMO Capital Markets dropped their target price on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an "outperform" rating for the company in a research report on Monday, April 1st. Barclays began coverage on shares of 4D Molecular Therapeutics in a research report on Monday, April 15th. They set an "overweight" rating for the company. HC Wainwright reiterated a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, June 7th. Finally, Jefferies Financial Group increased their target price on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a "buy" rating in a research report on Monday, April 1st. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $45.63.
View Our Latest Research Report on 4D Molecular Therapeutics
4D Molecular Therapeutics Company Profile
(
Get Free Report)
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
